touchFEATURE
Isatuximab demonstrated consistent PFS benefits across diverse patient profiles in RRMM in 2 pivotal trials
Learning Objectives
After watching these videos, participants should be better able to:
- Explain why isatuximab can be an appropriate and effective treatment in RRMM patients across diverse profiles such as those with lenalidomide refractoriness, high-risk cytogenetics, or renal impairment
- Discuss key efficacy and safety findings from the pivotal phase 3 IKEMA and ICARIA-MM trials, including subgroup analyses
- Summarise the robust design of the 2 pivotal trials
Overview
Isatuximab is a CD38-receptor–targeted monoclonal antibody approved as combination therapy for the treatment of certain patients who have received at least 1 prior line of therapy.6
In this activity, 3 short animated videos explore emerging clinical data from the pivotal, phase 3 IKEMA and ICARIA-MM trials (including subgroup analyses), which demonstrate that isatuximab can be an appropriate and effective treatment across diverse patient profiles in RRMM.1-5
PFS=progression-free survival; RRMM=relapsed and/or refractory multiple myeloma.
SARCLISA is indicated6:
- In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
- In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
